Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present)

References

• Cheng L, Gao E, Zhu F, et al. A case report on successful third Challenge to the pemetrexed-based regimen for advanced non-small cell lung cancer. Chin J Lung Cancer. 2019;22(6):395–400.
   Google Scholar
• Jones GS, Baldwin DR. Recent advances in the management of lung cancer. Clin Med (London Engl). 2018;18:41–46.
   PubMed Web of Science ®Google Scholar
• Zhao JG, Xiong JP. Advances on driver oncogenes of non-small cell lung cancer. Chin J Lung Cancer. 2015;19(1):42–47.
   Google Scholar
• Corsini MM, Miller RC, Haddock MG, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the mayo clinic experience (1975-2005). J Clin Oncol. 2008;26(21):3511–3516.
   PubMed Web of Science ®Google Scholar
• Hagiwara H, Sunada Y. Mechanism of taxane neurotoxicity. Breast Cancer. 2004;11(1):82–85.
   PubMedGoogle Scholar
• Robinson D, Wu Y, Lin S. The protein tyrosine kinase family of the human genome. Oncogene. 2000;19(49):5548–5557.
   PubMed Web of Science ®Google Scholar
• Cowan J. Structural biology of protein tyrosine kinases. Cell Mol Life Sci. 2006;63(22):2608–2625.
   PubMed Web of Science ®Google Scholar
• OuYang YQ, Zou WS, Peng L, et al. Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing 2,3-dihydro-indole or 1,2,3,4-tetrahydroquinoline as potential EGFR inhibitors. Eur J Med Chem. 2018;154:29–43.
   PubMed Web of Science ®Google Scholar
• Yarden Y. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol. 2001;2(2):127–137.
   PubMed Web of Science ®Google Scholar
• Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7(7):505–516.
   PubMed Web of Science ®Google Scholar
• Roskoski RJ. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74.
   PubMed Web of Science ®Google Scholar
• Shia J, Klimstra DS, Li AR, et al. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol. 2005;18:1348–1350.
   Google Scholar
• OuYang YQ, Wang CL, Zhao BB, et al. Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing oxazole or imidazole as potential EGFR inhibitors. New J Chem. 2018;42:17203–17215.
   Web of Science ®Google Scholar
• Wang X, Zhang S, MacLennan GT, et al. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin Cancer Res. 2007;13(3):953–957.
   PubMed Web of Science ®Google Scholar
• Kil S, Carlin C. EGF receptor residues Leu679, Leu680 mediate selective sorting of ligand-receptor complexes in early endosomal compartments. J Cell Physiol. 2000;185(1):47–60.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9(1):28–39.
   PubMed Web of Science ®Google Scholar
• Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol. 2008;21(2):16–22.
   Google Scholar
• Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study. Lancet. 2005;366(9496):1527–1537.
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol. 2003;21(12):2237–2246.
   PubMed Web of Science ®Google Scholar
• Moyer J, Barbacci E, Iwata K, et al. Induction of apoptosis and cell cycle arrest byCP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase]. Cancer Res. 1997;57(21):4838–4848.
   PubMed Web of Science ®Google Scholar
• Philip P, Mahoney M, Allmer C, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005;23(27):6657–6663.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang L, Wang Y, et al. Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer[J]. Chinese Med J. 2011;124(13):1933–1938.
   PubMed Web of Science ®Google Scholar
• Pampallona S. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–2743.
   PubMed Web of Science ®Google Scholar
• Yamane H, Ochi N, Yasugi M, et al. Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation. Onco Targets Ther. 2013;6(1):155–160.
   PubMedGoogle Scholar
• Shah R, Lester JF. Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non-small cell lung cancer: a clash of the generations. Clin Lung Cancer. 2019;21(3):216–228.
   Web of Science ®Google Scholar
• Ye X, Zhu ZZ, Zhong L, et al. High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact. J Thoracic Oncol. 2013;8(9):1118–1120.
   PubMed Web of Science ®Google Scholar
• Xu Y, Liu H, Chen J, et al. Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib. Cancer Biol Ther. 2010;9(8):572–582.
   PubMed Web of Science ®Google Scholar
• Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012;343(2):342–350.
   PubMed Web of Science ®Google Scholar
• Barf T, Kaptein A. Irreversible protein kinase inhibitors: balancing the benefits and risks. J Med Chem. 2012;55(14):6243–6262.
   PubMed Web of Science ®Google Scholar
• Coumar M, Chu C, Lin C, et al. Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification. J Med Chem. 2010;53(13):4980–4988.
   PubMed Web of Science ®Google Scholar
• Bose P, Ozer H. Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor forbreast and non-small cell lung cancer. Expet Opin Invest Drugs. 2009;18(11):1735–1751.
   PubMed Web of Science ®Google Scholar
• Zhou W, Ercan D, Chen L, et al. Novel mutant selective EGFR kinase inhibitors against EGFR (T790M). Nature. 2009;462(7276):1070–1074.
   PubMed Web of Science ®Google Scholar
• Ramalingam S, Blackhall F, Krzakowski M, et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2012;30(27):3337–3344.
   PubMed Web of Science ®Google Scholar
• Hassan K, Kadi NE, Davis A, et al. Abstract 4119: the development of EGFR resistant mutation, T790M, in lung adenocarcinoma is acquired through a specific cytosine deamination mechanism. Cancer Res. 2017;77(13):4119.
   Google Scholar
• Song Z, Ge Y, Wang C, et al. Challenges and perspectives on the development of small-molecule EGFR inhibitors against T790M-mediated resistance in non-small-cell lung cancer. J Med Chem. 2016;59:6580–6594.
   PubMed Web of Science ®Google Scholar
• Chuang J, Salahudeen A, Wakelee H. Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions. Expert Opin on Pharmacol. 2016;17(7):989–993.
   PubMed Web of Science ®Google Scholar
• Simmons A. Abstract 793: insulin-like growth factor 1 (IGF1R)/insulin receptor (INSR) inhibitory activity of rociletinib (CO-1686) and its metabolites in nonclinical models. Cancer Res. 2015;75(15):793.
   Google Scholar
• Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR (C797S) mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR (T790M). Nat Med. 2015;21(6):560–562.
   PubMed Web of Science ®Google Scholar
• Cross D, Ashton S, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046–1061.
   PubMed Web of Science ®Google Scholar
• Park K, Lee J, Han J, et al. 1300: efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose. J Thorac Oncol. 2016;11(4):113.
   Web of Science ®Google Scholar
• Patel H, Pawara R, Ansari A, et al. Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance. Eur J Med Chem. 2017;142:32–47.
   PubMed Web of Science ®Google Scholar
• Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small cell lung cancer. N Engl J Med. 2015;372:1689–1699.
   PubMed Web of Science ®Google Scholar
• Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Nat Acad Sci. 2008;105(6):2070–2075.
   PubMed Web of Science ®Google Scholar
• Zhang X, Gureasko J, Shen K, et al. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell. 2006;125:1137–1149.
   PubMed Web of Science ®Google Scholar
• Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995;1:1311–1318.
   PubMed Web of Science ®Google Scholar
• Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7:301–311.
   PubMed Web of Science ®Google Scholar
• Jia Y, Yun CH, Park E, et al. Overcoming EGFR (T790M) and EGFR (C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016;534(7605):129–132.
   PubMed Web of Science ®Google Scholar
• Metabomics Inc. Aminoquinazoline derivative and use thereof in preparing anti-malignant tumor medicament US2015065709A1. 2015.
   Google Scholar
• Univ Fudan. 6-furyl quinazoline-4-amine compound as well as preparation method and application thereof CN103772371A. 2014.
   Google Scholar
• Nanjing Mingde Drug R & D Co Ltd. Quinazoline compound used as EGFR (epidermal growth factor receptor) inhibitor CN108640928A. 2018.
   Google Scholar
• Jiangxi Science & Technology Normal University. Quinazoline compound containing cinnamamide structure and preparation method and application thereof CN106008480A. 2016.
   Google Scholar
• Jiangxi Science & Technology Normal University. Quinazoline compound containing aroyl hydrazine structure and application of quinazoline compound CN106866642A. 2017
   Google Scholar
• Yuqi J. Novel quinazoline inhibitor CN108658946A. 2017.
   Google Scholar
• Shanghi Inst Materia Medica CAS. Indole-1-carbonate compound and preparation method and application thereof CN108250187A. 2018.
   Google Scholar
• Hoffmann La Roche. Compounds WO2020002487A1. 2020.
   Google Scholar
• Hoffmann La Roche. Compounds US2020102299A1. 2020.
   Google Scholar
• Jiangxi Science & Technology Normal University. Pyrimidine compound containing substituted phenyl acrylamide structure and application of compound CN109280048A. 2018.
   Google Scholar
• Macau Science & Technology University. Method to treat lung cancer US9855250B1. 2016.
   Google Scholar
• Servier Lab. Combination between 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione and EGFR TYR kinase inhibitor WO2017021634A1. 2017.
   Google Scholar
• Nanjing Leikexing Biotechnology Co Ltd. Quinazoline, pyridopyrimidine or pyrimidopyrimidine derivative epidermal growth factor inhibitor and preparing method and application thereof CN106496196A. 2016.
   Google Scholar
• Allist Pharmaceuticals Inc. EGFR kinase inhibitor compound, preparation method and applications thereof WO2020038433A1. 2020.
   Google Scholar
• Jiangsu Hansoh Pharmaceutical; Shanghai Hansoh Biomedical Co Ltd. EGFR inhibitor, and preparation and application thereof WO2016054987A1. 2016.
   Google Scholar
• Beijing Puqi Medicine Tech Co Ltd. Nitrogen-containing heterocyclic compound, pharmaceutical composition and application thereof CN110790749A. 2019.
   Google Scholar
• Novartis AG. Methods for treating EGFR mutant cancersAvailable inPatent Translate Bibliographic data WO2016185333A1. 2016.
   Google Scholar
• Boehringer Ingelheim Int. New benzimidazole compounds and derivatives as EGFR inhibitors WO201916232A1. 2019.
   Google Scholar
• Taiho Pharmaceutical Co Ltd. Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof WO2013125709A1. 2014.
   Google Scholar
• Taiho Pharmaceutical Co Ltd. Exon 18 and/or exon 21 mutant EGFR selective inhibitor WO2019045036A1. 2019.
   Google Scholar
• Jiangsu Medolution Ltd. Substituted pyrimidines useful as EGFR-T790M kinase inhibitors WO2015117547A1. 2015.
   Google Scholar
• Shanghai Haiyan Pharmaceutical Technology Co Ltd. Arylamino pyrimidine compound and application thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom WO2015127873A1. 2015.
   Google Scholar
• Dalian Medical University. Diarylpyrimidine compound, composition and application CN105968056A. 2016.
   Google Scholar
• Genentech Inc. Azaindazole compounds as inhibitors of T790M containing EGFR mutants available in patent translate bibliographic data WO2014210354A1. 2018.
   Google Scholar
• Genentech Inc. Aminopyrimidine compounds as inhibitors of t790m containing EGFR mutants WO2014081718A1. 2017.
   Google Scholar
• Dana Farber Cancer Inst Inc. Pyrimidines as EGFR inhibitors and methods of treating disorders US20170362204A1. 2019.
   Google Scholar
• Jiangsu Hansoh Pharmaceutical; Shanghai Hansoh Biomedical Co Ltd. Inhibitors with ALK and EGFR dual activity, and preparation method and application thereof CN106187915A. 2016.
   Google Scholar
• Hefei Zhongke Precdo Biology Medicine Tech Co Ltd. Novel dual kinase inhibitor for EGFR and ALK CN106883213A. 2017.
   Google Scholar
• Chia Tai Tianqing Pharmaceutical Group Co Ltd. Aryl-phosphorus-oxygen compound as EGFR kinase inhibitor WO2019015655A1. 2019.
   Google Scholar
• Pfizer. 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders WO2015075598A1. 2015.
   Google Scholar
• Wenzhou Medical University. 6-substituted aminopurine compound acting on EGFR sensitive mutation kinase EGFR and EGFR (d746-750) and application of 6-substituted aminopurine compound CN105884777A. 2016.
   Google Scholar
• Xi’an Jiaotong University. 2,8,9-trisubstituted-9H-purine compounds, and salts and application thereof CN107892691A. 2018.
   Google Scholar
• Shenyang Pharmaceutical University. Purine compounds and application thereof CN110078732A. 2019.
   Google Scholar
• Wenzhou Medical University. Parazole[5,6-d]pyrimidine type EGFR inhibitor and anti-tumor activity thereof. CN105566329A. 2016.
   Google Scholar
• Precedo Pharmaceuticals Co Ltd. Novel EGFR wild-type and mutant kinase inhibitor WO2017114383A1. 2017.
   Google Scholar
• Guangzhou Inst Biomed & Healith. 7-oxopyridinopyrimidine compound as well as medicinal composition and application thereof WO2014079232A1. 2014.
   Google Scholar
• Jiangsu Aosaikang Pharm Co Ltd. Pyrimidopyridone or pyridopyridone compound and use thereof WO2019015593A1. 2019.
   Google Scholar
• Shanghai Inst Materia Medic CAS; Shanghai Haiyan Pharmaceutical Technology Co Ltd. Novel pyrimido-heterocyclic compound and preparation method and application thereof CN109305967A. 2019.
   Google Scholar
• Zhengzhou Tetranov Pharmaceutical Co Ltd. Pyrimidine ring-containing compound, EGFR inhibitor and application thereof WO2018050052A1. 2018.
   Google Scholar
• Wer A, Mansour TS. HKI-272, EKB-569, ErbB, EGFR, ErbB-1, HER2, ErbB-2, breast cancer, colorectal cancer, lung cancer. Cheminform. 2008;39(43):465–477.
   Google Scholar
• Soh J, Toyooka S, Ueno T, et al. Mechanisms and overcome of acquired resistance to EGFR tyrosine kinase inhibitors. Haigan. 2012;52(2):131–135.
   Google Scholar
• Ercan D, Zejnullahu K, Yonesaka K, et al. Amplification of EGFR (T790M) causes resistance to an irreversible EGFR inhibitor. Oncogene. 2010;29(16):2346–2356.
   PubMed Web of Science ®Google Scholar
• Singh M, Jadhav H. Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors. Drug Discov Today. 2018;23(3):745–753.
   PubMed Web of Science ®Google Scholar
• Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR (T790M) mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9(1):34.
   PubMedGoogle Scholar
• Planchard D, Brown KH, Kim DW, et al. Osimertinib western and asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemother Pharmacol. 2016;77(4):767–776.
   PubMed Web of Science ®Google Scholar